Access and download professional brochures to assist your practice.
By registering with PfizerPro.com, you'll gain access to exclusive services and customized content, including:
- Epocrates® Online Premium
- 5-Minute Clinical Consult
- A.D.A.M. QuickSheets for patients
Guidelines 
Click on a title to download or e-mail PDF.
The National Comprehensive Cancer Network (NCCN) has developed guidelines to evaluate and treat cancer patients who are experiencing heightened fatigue that interferes with activities of daily living.
Key Reprints
Please see below for a list of relevant SUTENT clinical study reprints offered by tumor type.
Click on a title to download or e-mail PDF.
Advanced RCC
Houk et al. Cancer Chemother Pharmacol. 2009. A
pharmacokinetic/pharmacodynamic meta-analysis investigating relationships between clinical endpoints and sunitinib exposure in patients with advanced solid tumors, including patients with gastrointestinal stromal tumor (GIST) and metastatic renal cell carcinoma (mRCC).
Motzer et al. J Clin Oncol. 2009. Final survival analyses and updated results from a randomized, phase III trial of 750 patients with previously untreated, metastatic renal cell carcinoma.
Cella D et al. J Clin Oncol. 2008. A report on the health-related quality-of-life (QOL) results from an international, randomized phase III trial comparing the efficacy of sunitinib versus interferon alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC).
Motzer et al. N Engl J Med. 2007. A phase III, multicenter, randomized trial of 750 patients with previously untreated, metastatic renal-cell carcinoma to receive either repeated 6-week cycles of sunitinib or interferon alfa.
Motzer et al. JAMA. 2006. A phase II, multicenter, open-label, single-arm, clinical trial to test the antitumor efficacy of sunitinib as second-line treatment in patients with metastatic clear-cell RCC.
Motzer et al. J Clin Oncol. 2006. A phase II, multicenter trial testing SU11248 (sunitinib malate) for clinical activity in patients with metastatic RCC.
GIST
Houk et al. Cancer Chemother Pharmacol. 2009. A pharmacokinetic/pharmacodynamic meta-analysis investigating relationships between clinical endpoints and sunitinib exposure in patients with advanced solid tumors, including patients with gastrointestinal stromal tumor (GIST) and metastatic renal cell carcinoma (mRCC).
Demetri et al. Lancet. 2006. A randomized multicenter trial to assess tolerability and anticancer efficacy of sunitinib in patients with advanced gastrointestinal stromal tumor who were resistant to or intolerant of previous treatment with imatinib.
Advanced pNET
Raymond et al. N Engl J Med. 2011. A multinational, randomized, double-blind, placebo-controlled, phase 3 trial that compared sunitinib vs placebo in patients with advanced, well-differentiated pancreatic neuroendocrine tumors.
